{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:01:57Z","timestamp":1792180917123,"version":"4.4.0"},"reference-count":182,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.clinthera.2017.03.013","type":"journal-article","created":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T19:01:38Z","timestamp":1494961298000},"page":"1244-1264","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists"],"prefix":"10.1016","volume":"39","author":[{"given":"Qiuhe","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2017.03.013_bib1","first-page":"V","article-title":"Is diabetes becoming the biggest epidemic of the twenty-first century?","volume":"1","author":"Tabish","year":"2007","journal-title":"Int J Health Sci"},{"key":"10.1016\/j.clinthera.2017.03.013_bib2","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/dc11-0442","article-title":"Globalization of diabetes: The role of diet, lifestyle, and genes","volume":"34","author":"Hu","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib3","unstructured":"World Health Organization\u00e3Diabetes Fact Sheet. http:\/\/www.who.int\/mediacentre\/factsheets\/fs312\/en\/. Accessed June 13, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.diabres.2013.11.002","article-title":"Global estimates of diabetes prevalence for 2013 and projections for 2035","volume":"103","author":"Guariguata","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clinthera.2017.03.013_bib5","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa0908292","article-title":"Prevalence of diabetes among men and women in China","volume":"362","author":"Yang","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2017.03.013_bib6","unstructured":"World map of obesity. http:\/\/www.worldobesity.org\/resources\/world-map-obesity\/?map=overview-men. Accessed August 10, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib7","first-page":"g6608","article-title":"NICE guidelines need specific BMI cut-off limits for Asians","volume":"349","year":"2014","journal-title":"Br Med J"},{"key":"10.1016\/j.clinthera.2017.03.013_bib8","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/868573","article-title":"Rising burden of obesity in Asia","author":"Ramachandran","year":"2010","journal-title":"Journal of Obesity"},{"key":"10.1016\/j.clinthera.2017.03.013_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2458-13-327","article-title":"Increasing trends in central obesity among Chinese adults with normal body mass index, 1993\u00e32009","volume":"13","author":"Du","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1016\/j.clinthera.2017.03.013_bib10","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0140-6736(15)00658-3","article-title":"Prevalence and trends in overweight and obesity among Chinese adults in 2004\u00e310: data from three nationwide surveys in China","volume":"386","author":"Jiang","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2017.03.013_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000443003","article-title":"Prevalence of overweight and obesity among Chinese adults: role of adiposity indicators and age","volume":"9","author":"Xu","year":"2016","journal-title":"Obesity Facts"},{"key":"10.1016\/j.clinthera.2017.03.013_bib12","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1210\/jc.2011-0585","article-title":"Obesity and type 2 diabetes: what can be unified and what needs to be individualized?","volume":"96","author":"Eckel","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.03.013_bib13","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1161\/CIRCULATIONAHA.111.067264","article-title":"Body fat distribution and risk of cardiovascular disease an update","volume":"126","author":"Despr\u00fb\u0300s","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2017.03.013_bib14","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1172\/JCI10842","article-title":"Obesity and insulin resistance","volume":"106","author":"Kahn","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2017.03.013_bib15","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.2337\/db10-0766","article-title":"Obesity and insulin resistance: an ongoing saga","volume":"59","author":"Kim","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.7326\/M14-2525","article-title":"Normal-weight central obesity: implications for total and cardiovascular mortality","volume":"163","author":"Sahakyan","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2017.03.013_bib17","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1056\/NEJMoa0801891","article-title":"General and abdominal adiposity and risk of death in Europe","volume":"359","author":"Pischon","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2017.03.013_bib18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jacc.2012.10.035","article-title":"Combining body mass index with measures of central obesity in the assessment of mortality in subjects with coronary disease: role of \u201cnormal weight central obesity\u201d","volume":"61","author":"Coutinho","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4239\/wjd.v5.i4.444","article-title":"Type 2 diabetes and cardiovascular disease: have all risk factors the same strength","volume":"5","author":"Mart\u00fb\u00d9n-Tim\u00fb\u030an","year":"2014","journal-title":"World Journal of Diabetes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2174\/157339910790909396","article-title":"Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance","volume":"6","author":"Masuo","year":"2010","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.clinthera.2017.03.013_bib21","first-page":"S1","article-title":"American Diabetes Association Standards of Medical Care in Diabetes 2016","volume":"39","author":"Cefalu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fendo.2013.00037","article-title":"Beta cell dysfunction and insulin resistance","volume":"4","author":"Cerf","year":"2013","journal-title":"Frontiers in Endocrinology"},{"key":"10.1016\/j.clinthera.2017.03.013_bib23","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/diaspect.21.3.160","article-title":"The pathophysiology of cardiovascular disease and diabetes: beyond blood pressure and lipids","volume":"21","author":"Dokken","year":"2008","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.clinthera.2017.03.013_bib24","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S1056-8727(00)00132-X","article-title":"Diabetes mellitus: a hypercoagulable state","volume":"15","author":"Carr","year":"2001","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clinthera.2017.03.013_bib25","unstructured":"Glucophage Prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020357s031,021202s016lbl.pdf. Accessed August 11, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"10.1016\/j.clinthera.2017.03.013_bib27","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1464-5491.2005.01554.x","article-title":"Does metformin decrease blood pressure in patients with type 2 diabetes intensively treated with insulin?","volume":"22","author":"Wulffele","year":"2005","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.clinthera.2017.03.013_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2796.2004.01328.x","article-title":"The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review","volume":"256","author":"Wulffel\u00fb\u0300","year":"2004","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2017.03.013_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/S1262-3636(03)72788-8","article-title":"Potential contribution of metformin to the management of cardiovascular disease risk in patients with abdominal obesity, the metabolic syndrome and type 2 diabetes","volume":"29","author":"Despres","year":"2003","journal-title":"Diabetes and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib30","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s11892-013-0363-2","article-title":"Interventions to preserve beta-cell function in the management and prevention of type 2 diabetes","volume":"13","author":"Page","year":"2013","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.clinthera.2017.03.013_bib31","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/dmrr.2443","article-title":"The beneficial effect of metformin on \u00f6\u0307-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes","volume":"29","author":"Bi","year":"2013","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2017.03.013_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s13300-014-0089-4","article-title":"Sodium glucose co-transporter-2 (SGLT2) inhibitors: A review of their basic and clinical pharmacology","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.clinthera.2017.03.013_bib33","unstructured":"Dapagliflozin Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/202293s003lbl.pdf. Accessed August 11, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib34","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/dom.12425","article-title":"Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects","volume":"17","author":"Tang","year":"2015","journal-title":"Diabetes Obesity Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib35","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2337\/dc10-0612","article-title":"Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise","volume":"33","author":"Ferrannini","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib36","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u00f6\u0307-cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.03.013_bib37","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1479164115585298","article-title":"Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes","volume":"12","author":"Sjostr\u00fb\u00d1m","year":"2015","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.clinthera.2017.03.013_bib38","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion","volume":"51","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib40","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib41","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib42","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00125-006-0510-2","article-title":"A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study","volume":"50","author":"Nauck","year":"2007","journal-title":"Diabetologia"},{"key":"10.1016\/j.clinthera.2017.03.013_bib43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-143-8-200510180-00006","article-title":"Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial","volume":"143","author":"Heine","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2017.03.013_bib44","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.clinthera.2007.11.006","article-title":"Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial","volume":"29","author":"Barnett","year":"2007","journal-title":"Clinical Therapy"},{"key":"10.1016\/j.clinthera.2017.03.013_bib45","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1463-1326.2009.01154.x","article-title":"Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study","volume":"11","author":"Davies","year":"2009","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib46","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2337\/dc08-1797","article-title":"One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial","volume":"32","author":"Bunck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib47","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib48","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1464-5491.2011.03301.x","article-title":"DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide","volume":"28","author":"Wysham","year":"2010","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.clinthera.2017.03.013_bib49","first-page":"464","article-title":"Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial","volume":"2","author":"Diamant","year":"2011","journal-title":"The Lancet: Diabetes and Endocrinology"},{"key":"10.1016\/j.clinthera.2017.03.013_bib50","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2337\/dc11-1107","article-title":"Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (duration-4): a 26-week double-blind study","volume":"35","author":"Russell-Jones","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib51","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.03.013_bib52","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.03.013_bib53","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2147\/VHRM.S3119","article-title":"Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes","volume":"4","author":"van de Laar","year":"2008","journal-title":"Journal of Vascular Health and Risk Management"},{"key":"10.1016\/j.clinthera.2017.03.013_bib54","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1046\/j.1463-1326.2001.00156.x","article-title":"Effect of acarbose on weight maintenance after dietary weight loss in obese subjects","volume":"3","author":"Hauner","year":"2001","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib55","first-page":"391","article-title":"Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman","volume":"18","author":"Nakhaee","year":"2013","journal-title":"Journal of Research in Medical Sciences"},{"key":"10.1016\/j.clinthera.2017.03.013_bib56","doi-asserted-by":"crossref","first-page":"269","DOI":"10.2337\/diacare.26.2.269","article-title":"Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin","volume":"26","author":"Phillips","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib57","doi-asserted-by":"crossref","first-page":"e79421","DOI":"10.1371\/journal.pone.0079421","article-title":"Comparisons of the efficacy of alpha glucosidase inhibitors on type 2 diabetes patients between Asian and Caucasian","volume":"8","author":"Cai","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2017.03.013_bib58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1475-2840-13-81","article-title":"On the potential of acarbose to reduce cardiovascular disease","volume":"13","author":"Standl","year":"2014","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1758-5996-6-68","article-title":"Post-meal \u00f6\u0307-cell function predicts the efficacy of glycemic control in patients with type 2 diabetes inadequately controlled by metformin monotherapy after addition of glibencl amide or acarbose","volume":"6","author":"Chen","year":"2014","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"10.1016\/j.clinthera.2017.03.013_bib60","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/dmrr.2553","article-title":"Profound defects in \u00f6\u0307-cell function in screen-detected type 2 diabetes are not improved with glucose-lowering treatment in the Early Diabetes Intervention Program (EDIP)","volume":"30","author":"Hannon","year":"2014","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clinthera.2017.03.013_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1463-1326.2004.00317.x","article-title":"The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study","volume":"6","author":"Rachmani","year":"2004","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib62","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.2337\/db14-0052","article-title":"Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors","volume":"63","author":"Omar","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib63","unstructured":"Onglyza Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/022350s014lbl.pdf. Accessed August 10, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib64","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2337\/dc14-2868","article-title":"Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib65","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/ijcp.12119","article-title":"Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial","volume":"67","author":"Goke","year":"2013","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.clinthera.2017.03.013_bib66","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1472-6823-14-17","article-title":"A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy","volume":"14","author":"White","year":"2014","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clinthera.2017.03.013_bib67","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1475-2840-11-6","article-title":"Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data","volume":"11","author":"Cobble","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib68","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1463-1326.2011.01417.x","article-title":"Effects of saxagliptin on \u00f6\u0307-cell stimulation and insulin secretion in patients with type 2 diabetes","volume":"13","author":"Henry","year":"2011","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib69","author":"Du","year":"2016","journal-title":"Assessing the efficacy and safety of saxagliptin and acarbose added to metformin in type 2 diabetes mellitus patients with inadequate glycemic control with metformin"},{"key":"10.1016\/j.clinthera.2017.03.013_bib70","first-page":"63","article-title":"The mode of action of thiazolidinediones","volume":"6","author":"Hauner","year":"2004","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib71","unstructured":"ACTOS Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021073s043s044lbl.pdf. Accessed August 10, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib72","unstructured":"Effect of pioglitazone and exenatide on body weight and beta cell function (PIO-EX). https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00845182. Accessed August 10, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib73","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1210\/jcem.87.6.8567","article-title":"Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients","volume":"87","author":"Miyazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.03.013_bib74","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.2337\/diacare.26.11.3148","article-title":"Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity","volume":"26","author":"Shadid","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib75","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2337\/diabetes.55.02.06.db05-1066","article-title":"Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes","volume":"55","author":"Xiang","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib76","first-page":"279","article-title":"Drugs for diabetes: part 2 sulphonylureas","volume":"17","author":"Smith","year":"2010","journal-title":"The British Journal of Cardiology"},{"key":"10.1016\/j.clinthera.2017.03.013_bib77","unstructured":"Amaryl Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020496s022lbl.pdf. Accessed August 10, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib78","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2013-2920","article-title":"Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus","volume":"98","author":"Kodama","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.03.013_bib79","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12933-015-0279-z","article-title":"Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study","volume":"14","author":"Simo","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib80","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.2337\/dc14-0398","article-title":"Effect of exenatide, sitagliptin, or glimepiride on \u00f6\u0307-cell secretory capacity in early type 2 diabetes","volume":"37","author":"Gudipaty","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib81","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1146\/annurev.me.36.020185.002241","article-title":"The molecular mechanism of insulin action","volume":"36","author":"Kahn","year":"1985","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clinthera.2017.03.013_bib82","unstructured":"Lantus Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021081s034lbl.pdf. Accessed August 12, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib83","unstructured":"Toujeo Prescribing information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206538lbl.pdf. Accessed August 12, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib84","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.2165\/00003495-200363160-00007","article-title":"Insulin glargine: an updated review of its use in the management of diabetes mellitus","volume":"63","author":"Dunn","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2017.03.013_bib85","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2337\/dc14-2548","article-title":"Effects of insulin glargine and liraglutide therapy on liver fat as measured by magnetic resonance in patients with type 2 diabetes: a randomized trial","volume":"38","author":"Tang","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib86","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-5491.2006.01881.x","volume":"23","author":"Gerstein","year":"2006","journal-title":"Diabetic Medicine"},{"key":"10.1016\/j.clinthera.2017.03.013_bib87","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.2337\/dc09-2361","article-title":"Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition","volume":"33","author":"Bunck","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3810\/pgm.2013.05.2660","article-title":"Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials","volume":"125","author":"Grimm","year":"2013","journal-title":"Postgrad Med"},{"key":"10.1016\/j.clinthera.2017.03.013_bib89","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1185\/03007990802282398","article-title":"Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes","volume":"24","author":"Forti","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.03.013_bib90","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/oby.2011.152","article-title":"Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes","volume":"19","author":"Sathyanarayana.","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.clinthera.2017.03.013_bib91","doi-asserted-by":"crossref","first-page":"740","DOI":"10.2337\/dc13-0467","article-title":"Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"37","author":"Jabbour","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib92","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/1753-0407.12357","article-title":"Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial","volume":"8","author":"Yang","year":"2016","journal-title":"Journal of Diabetes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib93","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.03.013_bib94","doi-asserted-by":"crossref","first-page":"38","DOI":"10.2478\/v10039-012-0078-7","article-title":"Comparative efficacy of exenatide versus insulin glargine on glycemic control in type 2 diabetes mellitus patients inadequately treated with metformin monotherapy","volume":"58","author":"Karagianni","year":"2013","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.clinthera.2017.03.013_bib95","doi-asserted-by":"crossref","first-page":"e50117","DOI":"10.1371\/journal.pone.0050117","article-title":"Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists","volume":"7","author":"Cuthbertson","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2017.03.013_bib96","doi-asserted-by":"crossref","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"},{"key":"10.1016\/j.clinthera.2017.03.013_bib97","author":"Mellander","year":"2016","journal-title":"Hypersensitivity events with dapagliflozin: a pooled analysis (Abstract #761)"},{"key":"10.1016\/j.clinthera.2017.03.013_bib98","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1210\/jc.2003-030861","article-title":"Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial","volume":"89","author":"Schernthaner","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2017.03.013_bib99","doi-asserted-by":"crossref","first-page":"980","DOI":"10.4158\/EP13148.OR","article-title":"Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea","volume":"19","author":"Liu","year":"2013","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.clinthera.2017.03.013_bib100","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1056\/NEJMoa075392","article-title":"Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes","volume":"375","author":"Holman","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2017.03.013_bib101","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33)","volume":"352","year":"1998","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2017.03.013_bib102","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.2337\/dc09-S301","article-title":"Defining and characterizing the progression of type 2 diabetes","volume":"32","author":"Fonseca","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib103","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00592-012-0451-9","article-title":"Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes","volume":"50","author":"Pistrosch","year":"2013","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib104","first-page":"306","article-title":"Delay in starting insulin after failure of other treatments in patients with type 2 diabetes mellitus","volume":"18","author":"Zografou","year":"2014","journal-title":"Hippokratia"},{"key":"10.1016\/j.clinthera.2017.03.013_bib105","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1472-6823-9-19","article-title":"The consequences of delaying insulin initiation in UK type 2 diabetes patients failing oral hyperglycaemic agents: a modelling study","volume":"9","author":"Goodall","year":"2009","journal-title":"BMC Endocr Disord"},{"key":"10.1016\/j.clinthera.2017.03.013_bib106","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1677\/ERC-09-0087","article-title":"Diabetes and cancer","volume":"16","author":"Vigneri","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clinthera.2017.03.013_bib107","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1053\/j.gastro.2009.04.013","article-title":"Anti-diabetic therapies affect risk of pancreatic cancer","volume":"137","author":"Li","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2017.03.013_bib108","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4158\/EP11097.OR","article-title":"Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus","volume":"18","author":"Levin","year":"2012","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.clinthera.2017.03.013_bib109","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1185\/03007995.2012.654850","article-title":"Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes","volume":"28","author":"Levin","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.03.013_bib110","first-page":"2677","article-title":"Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study","volume":"125","author":"Ge-heng","year":"2012","journal-title":"Chin Med J"},{"key":"10.1016\/j.clinthera.2017.03.013_bib111","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/joim.12293","article-title":"Comparison of the effects on glycaemic control and \u00f6\u0307-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: a multicentre randomized parallel-group trial (the CONFIDENCE study)","volume":"277","author":"Xu","year":"2015","journal-title":"J Intern Med"},{"key":"10.1016\/j.clinthera.2017.03.013_bib112","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12933-015-0178-3","article-title":"The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study","volume":"14","author":"Paul","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib113","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1185\/030079908X260862","article-title":"Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis","volume":"24","author":"Glass","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2017.03.013_bib114","doi-asserted-by":"crossref","first-page":"1892908.e1","DOI":"10.1016\/j.clinthera.2012.07.007","volume":"34","author":"Inagaki","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.03.013_bib115","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s13300-013-0037-8","article-title":"Using exenatide twice daily or insulin in clinical practice: results from CHOICE","volume":"4","author":"Mathieu","year":"2013","journal-title":"Diabetes Therapy"},{"key":"10.1016\/j.clinthera.2017.03.013_bib116","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/1477-7525-11-217","article-title":"Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study","volume":"11","author":"Reaney","year":"2013","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib117","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1177\/1060028013520597","article-title":"Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine","volume":"48","author":"Pawaskar","year":"2014","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.clinthera.2017.03.013_bib118","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2147\/DMSO.S41827","article-title":"Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries","volume":"6","author":"Ostenson","year":"2013","journal-title":"Diabetes Metabolic Syndrome and Obesity"},{"key":"10.1016\/j.clinthera.2017.03.013_bib119","first-page":"616","article-title":"Cardiovascular safety profile of currently available diabetic drugs","volume":"14","author":"Azimova","year":"2014","journal-title":"The Ochsner Journal"},{"key":"10.1016\/j.clinthera.2017.03.013_bib120","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1743-7075-7-83","article-title":"Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus","volume":"7","author":"Ito","year":"2010","journal-title":"Nutrition and Metabolism (London)"},{"key":"10.1016\/j.clinthera.2017.03.013_bib121","first-page":"27","article-title":"Effectiveness of metformin on weight loss in nondiabetic individuals with obesity","volume":"121","author":"Seifarth","year":"2013","journal-title":"Experimental and Clinical Endocrinology & Diabetes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib122","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.2337\/dc12-0719","article-title":"Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease","volume":"36","author":"Hong","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib123","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/1753-0407.12337","article-title":"Efficacy of acarbose and metformin in newly diagnosed type 2 diabetes patients stratified by HbA1c levels","volume":"8","author":"Zhang","year":"2016","journal-title":"Journal of Diabetes"},{"key":"10.1016\/j.clinthera.2017.03.013_bib124","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-8227(98)00062-X","article-title":"Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus","volume":"41","author":"Kado","year":"1998","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.clinthera.2017.03.013_bib125","doi-asserted-by":"crossref","first-page":"e0126704","DOI":"10.1371\/journal.pone.0126704","article-title":"Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis","volume":"10","author":"Gu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2017.03.013_bib126","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s12020-013-9970-6","article-title":"The effects of sulfonylureas plus metformin on lipids, blood pressure, and adverse events in type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"44","author":"Zhang","year":"2013","journal-title":"Endocrine"},{"key":"10.1016\/j.clinthera.2017.03.013_bib127","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2337\/diaspect.27.2.87","article-title":"Personalized diabetes management: moving from algorithmic to individualized therapy","volume":"27","author":"Subramanian","year":"2014","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.clinthera.2017.03.013_bib128","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2337\/dc14-1630","article-title":"Weight management in type 2 diabetes: current and emerging approaches to treatment","volume":"38","author":"Van","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib129","first-page":"429","article-title":"Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk","volume":"9","author":"Zou","year":"2013","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2017.03.013_bib130","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12933-016-0393-6","article-title":"Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis","volume":"15","author":"Hoogwerf","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib131","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12933-016-0356-y","article-title":"Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis","volume":"15","author":"Sonesson","year":"2016","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib132","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2337\/dc11-1693","article-title":"Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy","volume":"35","author":"Rosenstock","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib133","doi-asserted-by":"crossref","DOI":"10.4158\/EP.14.3.285","article-title":"Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus","volume":"14","author":"Sheffield","year":"2008","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.clinthera.2017.03.013_bib134","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jfma.2012.02.027","article-title":"Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus","volume":"112","author":"Lu","year":"2013","journal-title":"Journal of the Formosan Medical Association"},{"key":"10.1016\/j.clinthera.2017.03.013_bib135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/dmrr.2561","article-title":"Benefits of exenatide on obesity and NAFLD with elevated liver enzymes in patients with type 2 diabetes","volume":"30","author":"Shao","year":"2014","journal-title":"Diabetes Metabolism Research and Reviews"},{"key":"10.1016\/j.clinthera.2017.03.013_bib136","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jdiacomp.2016.01.013","article-title":"Gender related different effects of a combined therapy of exenatide and metformin on overweight or obesity patients with type 2 diabetes mellitus","volume":"30","author":"Quan","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.clinthera.2017.03.013_bib137","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1507\/endocrj.EJ14-0009","article-title":"Effects of exenatide on metabolic parameters\/control in obese Japanese patients with type 2 diabetes","volume":"61","author":"Tokuda","year":"2014","journal-title":"Endocr J"},{"key":"10.1016\/j.clinthera.2017.03.013_bib138","doi-asserted-by":"crossref","first-page":"91","DOI":"10.4103\/2230-8210.107804","article-title":"Clinical experience with exenatide in obese North Indian patients with type 2 diabetes mellitus","volume":"17","author":"Bawa","year":"2013","journal-title":"Indian Journal of Endocrinology and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib139","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.2040-1124.2012.00238.x","article-title":"Efficacy and safety of exenatide once-weekly vs exenatide twice-daily in Asian patients with type 2 diabetes mellitus","volume":"4","author":"Ji","year":"2013","journal-title":"Journal of Diabetes Investiagtion"},{"key":"10.1016\/j.clinthera.2017.03.013_bib140","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.clinthera.2008.08.006","article-title":"Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study","volume":"30","author":"Moretto","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2017.03.013_bib141","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1463-1326.2006.00589.x","article-title":"Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in overweight metformin treated patients with type 2 diabetes mellitus","volume":"8","author":"Ratner","year":"2006","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib142","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.03.013_bib143","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.2040-1124.2010.00084.x","article-title":"Improved glycemic control and reduced bodyweight with exenatide: a double-blind, randomized, phase 3 study in Japanese patients with sub-optimally controlled type 2 diabetes over 24 weeks","volume":"2","author":"Kadowaki","year":"2011","journal-title":"Journal of Diabetes Investigation"},{"key":"10.1016\/j.clinthera.2017.03.013_bib144","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis","volume":"3","author":"Robinson","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2017.03.013_bib145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/ajh.2009.245","article-title":"Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes","volume":"23","author":"Okerson","year":"2010","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.clinthera.2017.03.013_bib146","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajh\/hpt196","article-title":"Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression","volume":"27","author":"Katout","year":"2014","journal-title":"American Journal of Hypertension"},{"key":"10.1016\/j.clinthera.2017.03.013_bib147","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/dom.12085","article-title":"Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials","volume":"15","author":"Wang","year":"2013","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib148","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/bcp.12843","article-title":"Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males","volume":"81","author":"Smits","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib149","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.2337\/diacare.15.10.1258","article-title":"Effect of insulin therapy on blood pressure in NIDDM patients with secondary failure","volume":"15","author":"Randeree","year":"1992","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib150","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/eurheartj\/ehn567","article-title":"Development of life-expectancy tables for people with type 2 diabetes","volume":"30","author":"Leal","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2017.03.013_bib151","first-page":"55","article-title":"Mortality, outcomes, and healthcare costs in T2DM patients at risk for cardiovascular disease","volume":"3","author":"Kern","year":"2013","journal-title":"American Journal of Accountable Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib152","unstructured":"European Association for the Study of Diabetes (EASD) guidelines. https:\/\/www.escardio.org\/static_file\/Escardio\/education\/eLearning\/webinars\/general-cardiology\/guidelines_impmeetingdiabetes_1Ryden.pdf. Accessed September 12, 2016."},{"issue":"6","key":"10.1016\/j.clinthera.2017.03.013_bib153","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib154","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.2337\/dc14-0876","article-title":"Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes","volume":"37","author":"Diamant","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib155","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2017.03.013_bib156","unstructured":"INTERNATIONAL DIABETES FEDERATION, 2012 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes. Accessed September 12, 2016. http:\/\/www.idf.org\/e-library\/guidelines\/79-global-guideline-for-type-2-diabetes."},{"key":"10.1016\/j.clinthera.2017.03.013_bib157","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.2337\/dc11-0291","article-title":"Effects of exenatide on measures of \u00f6\u0307-cell function after 3 years in metformin-treated patients with type 2 diabetes","volume":"34","author":"Bunck","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib158","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00592-014-0638-3","article-title":"Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes","volume":"51","author":"Bi","year":"2014","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.clinthera.2017.03.013_bib159","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Current Medical Research Opinion"},{"key":"10.1016\/j.clinthera.2017.03.013_bib160","doi-asserted-by":"crossref","DOI":"10.1089\/dia.2016.0107","article-title":"Efficacy and Tolerability of exenatide once weekly over 6 years in patients with type 2 diabetes: an uncontrolled open-label extension of the DURATION-1 study","author":"Henry","year":"2016","journal-title":"Diabetes Technology and Therapeutics"},{"key":"10.1016\/j.clinthera.2017.03.013_bib161","doi-asserted-by":"crossref","first-page":"157201","DOI":"10.1155\/2015\/157201","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"2015","author":"Sun","year":"2015","journal-title":"Journal of Diabetes Research"},{"key":"10.1016\/j.clinthera.2017.03.013_bib162","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib163","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/j.1463-1326.2010.01309.x","article-title":"Changes in body composition after 9 months of treatment with exenatide twice daily versus glimepiride: comment letter on Jendle et al","volume":"12","author":"Gallwitz","year":"2010","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib164","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","article-title":"Long-term drug treatment for obesity: a systematic and clinical review","volume":"311","author":"Yanovski","year":"2014","journal-title":"Journal of American Medical Association"},{"key":"10.1016\/j.clinthera.2017.03.013_bib165","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/107424840300800402","article-title":"Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance","volume":"8","author":"Watson","year":"2003","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2017.03.013_bib166","doi-asserted-by":"crossref","first-page":"463","DOI":"10.5114\/aoms.2015.52350","article-title":"Central obesity, type 2 diabetes and insulin: exploring a pathway full of thorns","volume":"11","author":"Papaetis","year":"2015","journal-title":"Archives of Medical Science"},{"key":"10.1016\/j.clinthera.2017.03.013_bib167","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4103\/1947-2714.132916","article-title":"Atherosclerotic cardiovascular disease risk and evidence-based management of cholesterol","volume":"6","author":"Roy","year":"2014","journal-title":"New American Journal of Medical Science"},{"key":"10.1016\/j.clinthera.2017.03.013_bib168","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3803\/EnM.2016.31.1.80","article-title":"Effects of short-term exenatide treatment on regional fat distribution, glycated hemoglobin levels, and aortic pulse wave velocity of obese type 2 diabetes mellitus patients","volume":"31","author":"Hong","year":"2016","journal-title":"Endocrinology and Metabolism (Seoul, Korea)"},{"key":"10.1016\/j.clinthera.2017.03.013_bib169","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomised clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour.","year":"2016","journal-title":"Diabetes Obesity and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib170","doi-asserted-by":"crossref","first-page":"E947","DOI":"10.1152\/ajpendo.00400.2015","article-title":"Exenatide exerts direct protective effects on endothelial cells through AMPK\/Akt\/eNOS pathway in a GLP-1 receptor dependent manner","volume":"310","author":"Wei","year":"2016","journal-title":"American Journal of Physiology, Endocrinology and Metabolism"},{"key":"10.1016\/j.clinthera.2017.03.013_bib171","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2017.03.013_bib172","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clinthera.2017.03.013_bib173","unstructured":"Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01144338. Accessed September 13, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib174","unstructured":"A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01455896. Accessed September 13, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib175","unstructured":"Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN\u00e3\u00ad\u00c2 6). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01720446. Accessed September 13, 2016."},{"key":"10.1016\/j.clinthera.2017.03.013_bib176","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2017.03.013_bib177","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2017.03.013_bib178","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib179","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S2213-8587(13)70214-6","article-title":"Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study","volume":"2","author":"Pratley","year":"2014","journal-title":"The Lancet Diabetes and Endocrinology"},{"key":"10.1016\/j.clinthera.2017.03.013_bib180","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2017.03.013_bib181","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"The Lancet"},{"key":"10.1016\/j.clinthera.2017.03.013_bib182","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1463-1326.2011.01393.x","article-title":"Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit","volume":"13","author":"Thong","year":"2011","journal-title":"Diabetes Obesity and Metabolism"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817301959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291817301959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T16:23:14Z","timestamp":1535818994000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291817301959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":182,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0149291817301959"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.03.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2017.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}